AAV-EGFP mice had significantly increased liver weights compared with WT controls, as expected given the substantial hepatic steatosis known to occur in this model of CGL2, mimicking the human condition.8, 9, 10, 11 Liver weights in AAV-hBSCL2 mice were significantly decreased compared with AAV-EGFP 19 weeks after AAV-hBSCL2 injection. This evidence concerns the gene GZMH and fatty liver disease.